Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas E. Hutson, Sun Young Rha, J.R. Merchan, Eric Winquist, Howard Gurney, Viktor Grünwald, S. George, Julia F. Markensohn, Joseph E. Burgents, Răzvan Cristescu, Perminder S. Sachdev, Y. Narita, Jie Huang, Zi-Ming Zhao, Chinyere E. Okpara, Yukinori Minoshima, Toni K. Choueiri